Pharmacological intensification is one of the most important factors needed to get more patients to reach goals in type 2 diabetes mellitus (DM2). The objective of this research protocol is to demonstrate the degree of metabolic control in patients with DM2 and their glycemic control at 3, 6 months and 1 year after their pharmacological intensification in a Low Cost Diabetes Care Center (CAD). Descriptive, cross-sectional and retrospective study from 2019 to 2022, an HbA1c ≤ 7% was considered a meta control. Of the 422 patients studied, 66.8% (n=282/422) were women and 33.2% men. 33.2% comprised the 3-month cohort, 20.4% at 6 months, and 46.4% at 1 year. At the start of treatment in CAD, 81% of the patients were outside the goals, of these, 31.5% had an A1C between 7.1-9%, 49.4% between 9.1-12% and 19% ≥12.1%. Regarding treatment, 12.6% had no drug treatment, 34.6% monotherapy, 45.7% double oral therapy, 6.6% triple and 0.5% quadruple. 20.1% of the participants used insulin and 0.9% GLP-1. 78.9% were taking metformin, 36.7% sulfonylureas, 15.4% IDPP4, 6.2% ISGLT2, 5.9% acarbose, and 4.7% TZDs. During pharmacological intensification there was an increase in the use of medications: Metformin +18.3%, IDPP4 +26.1%, iSGLT2 +25.8% and TZD +12.4%. Glibenclamide was reduced to -6%, all of them statistically significant (p=0.000). Patients without treatment decreased from 12.6 to 1.4% (p= 0.005) and in monotherapy from 34.6 to 15.9% (p= 0.000), dual therapy increased from 45.7 to 50.9%, triple from 6.6 to 27% and quadruple from 0.5 to 4.7% (p=0.003). The use of insulin doubled from 20.81 to 44.3%, likewise GLP-1 from 0.9 to 6.4%; both were statistically significant (p=.000). According to glycemic control, at 3 months 89.3% improved their glucose levels and 35% of the participants reached control goals, at 6 months 94.2% improved their glucose levels and 53. 5% achieved their control goals. At one year, 90.3% improved their glucose levels and 71.4% reached control goals.

Disclosure

R. Violante: None. N. Fernandez: None. D. Salguero: None. H. Gutierrez: None.

Funding

None

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.